Antagonist Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Antagonist Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Antagonist Development Program Today - Breaking & Trending Today

Liminal BioSciences Provides R&D Update

Published: June 2, 2023

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead...

Source: prnewswire.com

Related Topics:

United KingdomBruce PritchardLiminal Biosciences IncFairhaven Pharmaceuticals IncWorld Health OrganisationAgonist Development ProgramAntagonist Development ProgramMarket Watch ResearchChief Executive OfficerWatch ResearchFuture Market InsightsGary BridgerInterim Chief Scientific OfficerStudy ResultsLiminal Biosciences Inc

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

Published: June 2, 2023

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)

Source: finanznachrichten.de

Related Topics:

United KingdomShrinal InamdarBruce PritchardKaitlin GallagherExchange CommissionWorld Health OrganisationMarket Watch ResearchSecurities ExchangeFairhaven Pharmaceuticals IncLiminal Biosciences IncAgonist Development ProgramAntagonist Development ProgramPrnewswire Liminal Biosciences IncChief Executive OfficerWatch ResearchFuture Market InsightsGary BridgerInterim Chief Scientific OfficerStudy ResultsAbout Liminal BiosciencesSecurities ActSecurities Exchange ActLiminal BioscienceNasdaq Listing RuleNasdaq Capital Market